Cryoport, Inc. (NASDAQ:CYRX) Stake Increased by Franklin Resources Inc.

Franklin Resources Inc. boosted its holdings in shares of Cryoport, Inc. (NASDAQ:CYRX) by 5.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 385,619 shares of the company’s stock after buying an additional 20,077 shares during the period. Franklin Resources Inc. owned approximately 0.78% of Cryoport worth $3,127,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its holdings in shares of Cryoport by 9.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock valued at $122,000 after acquiring an additional 1,534 shares in the last quarter. Rhumbline Advisers increased its position in Cryoport by 3.4% in the 2nd quarter. Rhumbline Advisers now owns 64,158 shares of the company’s stock worth $443,000 after purchasing an additional 2,086 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Cryoport by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after purchasing an additional 2,226 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cryoport during the 3rd quarter valued at about $82,000. Finally, Quest Partners LLC grew its stake in shares of Cryoport by 1,083,000.0% in the 2nd quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock valued at $75,000 after buying an additional 10,830 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Stock Up 2.3 %

Cryoport stock opened at $7.87 on Thursday. The firm has a market cap of $389.02 million, a price-to-earnings ratio of -2.33 and a beta of 1.62. The firm has a fifty day moving average price of $7.42 and a two-hundred day moving average price of $7.95. Cryoport, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $20.10. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CYRX. Roth Mkm cut their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. UBS Group lifted their price objective on shares of Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday, October 18th. Finally, Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cryoport has an average rating of “Moderate Buy” and a consensus target price of $12.29.

Insider Buying and Selling

In related news, Director Ramkumar Mandalam sold 7,369 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the transaction, the director now directly owns 59,497 shares in the company, valued at $443,847.62. This represents a 11.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jerrell Shelton sold 50,000 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $6.51, for a total transaction of $325,500.00. Following the completion of the sale, the chief executive officer now directly owns 731,897 shares of the company’s stock, valued at approximately $4,764,649.47. This trade represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 109,869 shares of company stock valued at $735,673. Insiders own 10.10% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.